We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The U.S. District Court for the Southern District of New York did not “abuse its discretion” in granting a preliminary injunction against Apotex blocking further sales of its generic Plavix pending the outcome of the patent challenge, a federal appeals court determined (DID, Dec. 11).
The U.S. Court of Appeals for the Federal Circuit sustained a preliminary injunction blocking sales of clopidogrel bisulfate, a generic version of Plavix, Bristol-Myers Squibb (BMS) and sanofi-aventis announced Dec 8.
Two days after the FDA gave the green light to market a generic version of Savient’s prescription weight-gain drug, Oxandrin, a federal district court granted a request by the patent holder seeking to block all sales and marketing of any generic version of the drug pending the outcome of patent litigation. Read More
Two days after the FDA gave the green light to market a generic version of Savient’s prescription weight-gain drug, Oxandrin, a federal district court granted a request by the patent holder seeking to block all sales and marketing of any generic version of the drug pending the outcome of patent litigation. Read More
The FDA granted pediatric exclusivity for insomnia drugs Ambien and Ambien CR, giving sanofi-aventis six more months of patent protection, the company announced. Read More
Generic drug manufacturer Teva Pharmaceutical and its subsidiary Sicor will continue marketing the cancer drug idarubicin and the antibiotic azithromycin, the generic versions of Pfizer's Idamycin and Zithromax, according to the terms of a settlement agreement the two companies have reached. Read More
Australian generic drug manufacturer Mayne Pharma lost its appeal in federal court attempting to overturn a lower court’s decision that found its formulation for propofol infringed on patents held by AstraZeneca.
Shire Laboratories has filed a patent infringement lawsuit against Andrx Pharmaceuticals and Watson Pharmaceuticals to stop the companies’ from marketing a generic form of Shire’s ADHD treatment drug, Adderall XR.
The European Patent Office (EPO) issued an opinion upholding Pfizer’s Lipitor patent, siding with the company in a patent infringement case filed by generic drugmaker Ranbaxy.